SAN DIEGO, March 7, 2012 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is
offering to sell shares of its common stock in an underwritten
public offering.
Credit Suisse Securities (USA)
LLC is acting as sole book-running manager and underwriter in this
offering.
A registration statement relating to the shares described above
was previously filed with and has become effective by rule of the
Securities and Exchange Commission (SEC). A final prospectus
supplement relating to the offering will be filed with the SEC and
will be available on the SEC's website at http://www.sec.gov.
Copies of the final prospectus supplement and related prospectus,
when available, may be obtained from Credit Suisse Securities
(USA) LLC, Attention: Prospectus
Department, One Madison Avenue, New York,
NY 10010, or by telephone at (800) 221-1037, or by e-mail at
newyork.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
the shares in any state or other jurisdiction which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin is committed
to delivering novel therapies that transform the way diabetes and
other metabolic disorders are treated. Amylin is headquartered in
San Diego, Calif. and has a
commercial manufacturing facility in Ohio.
This press release contains forward-looking statements about
Amylin and its public offering of common stock, which involve risks
and uncertainties. Actual results could differ materially from
those discussed or implied in this press release due to a number of
risks and uncertainties, including risks associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed offering, as well as risks that BYETTA®
(exenatide) injection, SYMLIN® (pramlintide acetate) injection or
BYDUREON™ (exenatide extended-release for injectable suspension),
and the revenues or royalties generated from these products, may be
affected by competition, unexpected new data, safety and technical
issues, or manufacturing and supply issues; risks that our
financial results may fluctuate significantly from period to period
and may not meet market expectations; risks that any financial
guidance we provide may not be accurate; risks that our clinical
trials will not be completed when planned, may not replicate
previous results, may not be predictive of real world use or may
not achieve desired end-points; risks that our preclinical studies
may not be predictive; risks that our NDAs for product candidates
or sNDAs for label expansion requests, may not be submitted timely
or receive FDA approval; risks that the launch of BYDUREON will be
unsuccessful; risks that we will not be successful in our efforts
to expand the reach of our sales force or in our efforts to secure
an exenatide development and commercial partner outside the U.S.;
risks that our expense reductions will not be as large as we
expect; and other risks inherent in the drug development and
commercialization process. Commercial and government reimbursement
and pricing decisions and the pace of market acceptance may also
affect the potential for BYETTA, SYMLIN or BYDUREON. These and
additional risks and uncertainties are described more fully in the
Company's recently filed Annual Report on Form 10-K.
Amylin disclaims any obligation to update these
forward-looking statements.
SOURCE Amylin Pharmaceuticals, Inc.